Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02096952 · ClinicalTrials.gov registry record · Phase 4
Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT02096952: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT02096952 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02096952, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether methylphenidate hydrochloride extended release liquid formulation is safe and effective in the treatment of attention-deficit/hyperactivity disorder (ADHD) in high-functioning adults with autism spectrum disorders (ASD).
Interventions
- DRUG Methylphenidate extended-release liquid formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-05 |
| Est. Completion | 2018-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02096952
The ClinicalTrials.gov registry entry for NCT02096952 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Methylphenidate extended-release liquid formulation is the first listed.
NCT02096952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02096952 about?
NCT02096952 is a clinical study titled "Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD". The purpose of this study is to determine whether methylphenidate hydrochloride extended release liquid formulation is safe and effective in the treatment of attention-deficit/hyperactivity disorder (ADHD) in high-functioning adults with autism spectrum disorders (ASD).
What is the current status of trial NCT02096952?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2014-05. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02096952?
The interventions under investigation include: Methylphenidate extended-release liquid formulation (DRUG).
Who is sponsoring clinical trial NCT02096952?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.